Drug Compounding Can't Be Justified By Price, FDA Says
Guidance on compounding commercially available drugs states that prescribers can order them as long as there's a clinical difference for the patient – a standard that likely helps Daraprim but not Lucentis.
You may also be interested in...
FDA wants more companies to adopt continuous manufacturing, which could expand the US manufacturing base.
A month after compounding pharmacists' latest annual visit to Congress, FDA has acted on one of their chief complaints – investigators citing them for GMP violations even in cases where the agency later acknowledged they were exempt.
In theory, reviewing generic applications faster should speed competition; in practice, FDA's new policy likely won't make too much difference.